Beneficial Influence of Agomelatine Treatment on Behavioral Impairments in AΒ-Induced Rat Model of Alzheimer’s Disease
| Autor: | Kalina Ilieva, Milena Atanasova, Jana Tchekalarova, Lidiya Petrova |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
business.industry Alzheimer‘s disease Public health Rat model General Engineering Pharmacy Disease 030226 pharmacology & pharmacy amyloid-beta Clinical pharmacy 03 medical and health sciences 0302 clinical medicine Internal medicine depression Medicine Agomelatine business agomelatine 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Journal of Biomedical and Clinical Research. 13:116-121 |
| ISSN: | 1313-9053 |
| DOI: | 10.2478/jbcr-2020-0016 |
| Popis: | Summary An increased risk of developing Alzheimer’s disease (AD) exists in patients with a history of depression. In the present study, we demonstrated that chronic agomelatine intraperitoneal treatment, at a dose of 40 mg/ kg for 21 days, starting one month after inducing AD by intracerebroventricular injection of amyloid-beta (Aβ) corrected anhedonia, decreased anxiety, and showed a potential to mitigate working memory errors during the last session in a radial arm maze. Altogether, our findings suggest that chronic agomelatine administration treatment could alleviate the burden of AD and may be considered a promising therapeutic approach to some adverse symptoms caused by the disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|